Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Levaquin Review Could Affect Bristol's Positioning Of Tequin

Executive Summary

The upcoming advisory committee review of a new indication for Ortho McNeil's Levaquin (levofloxacin) could affect Bristol-Myers Squibb's positioning of its pending quinolone antibiotic Tequin (gatifloxacin).

You may also be interested in...



Sepracor Xopenex

Abbott will co-promote levalbuterol. Sepracor currently markets the single-isomer form of the asthma drug albuterol using its own 65-person sales force and a 155-person contract sales force provided by Innovex (1"The Pink Sheet" Oct. 11, p. 23). Including Abbott, there are now over 500 reps supporting Xopenex, Sepracor said

Sepracor Xopenex

Abbott will co-promote levalbuterol. Sepracor currently markets the single-isomer form of the asthma drug albuterol using its own 65-person sales force and a 155-person contract sales force provided by Innovex (1"The Pink Sheet" Oct. 11, p. 23). Including Abbott, there are now over 500 reps supporting Xopenex, Sepracor said

Ortho-McNeil Levaquin

The anti-infectives committee will review levofloxacin for the treatment of community acquired pneumonia due to penicillin-resistant S. pneumonia on the afternoon of Oct. 20. The committee will consider development of antimicrobial drugs for the treatment of catheter-related blood stream infections in the morning session, beginning at 9 a.m

Related Content

UsernamePublicRestriction

Register

PS035006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel